Lilly begins shipping weight-loss pill Foundayo through LillyDirect

Eli Lilly began shipping Foundayo (orforglipron), its once-daily GLP-1 pill for weight loss, through its LillyDirect pharmacy on April 6, 2026, five days after the FDA approved it ^[1][5]. Lilly said prescriptions were accepted immediately and that wider availability through U.S. retail pharmacies and telehealth providers would follow shortly after ^[1]; Reuters reported that broader distribution began April 9 ^[5]. Foundayo is approved for adults with obesity, or overweight adults who also have a weight-related medical condition, to be used alongside a reduced-calorie diet and more physical activity ^[1]. Lilly describes it as the only GLP-1 weight-loss pill that can be taken at any time of day without restrictions on food or water ^[1]. Novo Nordisk's oral Wegovy pill reached the market in January 2026 ^[4].

What the pricing looks like

For people paying without insurance, LillyDirect lists the 0.8 mg starting dose and the 2.5 mg dose at $149 a month, the 5.5 mg dose at $199, and the 9 mg, 14.5 mg and 17.2 mg doses at $299 ^[2]. Prices for the 2.5 mg and 5.5 mg doses are temporarily reduced through December 31, 2026, and the 14.5 mg and 17.2 mg prices apply when a prescription is refilled within 45 days ^[2]. Lilly said eligible patients with commercial insurance may pay as little as $25 a month through a savings card, with savings applied automatically through LillyDirect; government beneficiaries are excluded from that card ^[1][2]. Eligible Medicare Part D patients may be able to get Foundayo for $50 a month beginning as soon as July 1, 2026 ^[1]. A separate legal analysis describes a federal pricing agreement under which Medicare begins covering weight-loss drugs for eligible beneficiaries on July 1, 2026, capping the monthly Medicare price for Ozempic, Wegovy, Mounjaro and Zepbound at $245 with a $50 monthly copay for beneficiaries ^[4].

The trial numbers

In the ATTAIN-1 trial, which randomized 3,127 adults with obesity or overweight plus at least one related condition across 10 countries for 72 weeks, people taking the highest dose who stayed on treatment lost an average of 27.3 pounds, or 12.4%, compared with 2.2 pounds, or 0.9%, on placebo ^[1]. Counting everyone who enrolled regardless of whether they finished, those on Foundayo lost an average of 25 pounds (11.1%) versus 5.3 pounds (2.1%) on placebo ^[1]. Lilly said the drug also reduced waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure across all doses tested ^[1].

Early demand

Foundayo was prescribed 1,390 times in the U.S. in its first week, according to analysts citing IQVIA data; that figure is likely based on about two days of capture for the week ended April 10 ^[5][6]. Lilly cautioned in an email to Reuters that early weekly figures are not comprehensive, may not capture all pharmacy partners, and are "best interpreted over time rather than as a complete count" ^[5]. By comparison, Novo's oral Wegovy recorded 3,071 U.S. prescriptions in its first four days after a January 5 launch, and 113,354 prescriptions in the same week Foundayo launched, up from 105,366 the prior week ^[5]. RBC Capital Markets analyst Trung Huynh said weeks 8 to 12 represent the earliest window to assess Foundayo's commercial momentum ^[5]. Lilly shares rose more than 2% on the Friday the data circulated, and CEO David Ricks said at a conference that the pill offers convenience, including for people who want to "graduate" from injectables after reaching weight-loss goals ^[5].

Why it matters for patients

Foundayo adds an oral option to a market long dominated by injections, which could appeal to people who want to avoid needles ^[4]. Its convenience claim is specific: no timing around meals or water ^[1]. Cost will depend heavily on insurance status and dose. The $25-a-month commercial figure requires coverage plus an eligible savings card and excludes government beneficiaries ^[1][2], while uninsured buyers face $149 to $299 a month depending on dose and refill timing ^[2]. Foundayo is not recommended for use with other GLP-1 medicines, and it is not known whether it is safe or effective in children ^[1]. It carries a warning that it may cause thyroid tumors, including thyroid cancer, and common side effects include nausea, constipation, diarrhea, vomiting, indigestion, stomach pain, headache, swollen belly, tiredness, belching, heartburn, gas and hair loss ^[1]. How it compares directly with injectable GLP-1s in head-to-head testing has not been reported.

What happens next

Medicare Part D coverage for eligible patients could start as soon as July 1, 2026, at $50 a month ^[1][4]. Lilly has submitted orforglipron for weight management or type 2 diabetes in more than 40 countries and plans to launch in each shortly after approval ^[1]. Post-approval safety work required by the FDA includes longer-term tracking of thyroid cancer risk and registries following children and pregnant women exposed to the drug, though the specific completion dates have not been disclosed ^[6].